Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group announced inducement equity awards to 12 newly hired non-executive employees. The awards include non-qualified stock options to purchase 19,390 shares at $12.02 per share and restricted stock units representing 38,810 shares. The options have a 10-year term with 25% vesting after one year and the remainder monthly over three years. The restricted stock units vest in four annual installments starting November 15, 2025. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the Company's 2018 Equity Incentive Plan terms.
Replimune Group ha annunciato premi azionari di incentivazione per 12 nuovi dipendenti non esecutivi. I premi includono opzioni di acquisto di azioni non qualificate per l'acquisto di 19.390 azioni a 12,02 $ per azione e unità azionarie vincolate che rappresentano 38.810 azioni. Le opzioni hanno una durata di 10 anni con un 25% di maturazione dopo un anno e il resto mensilmente per tre anni. Le unità azionarie vincolate maturano in quattro rate annuali a partire dal 15 novembre 2025. Questi premi sono stati approvati secondo la Regola di Registrazione Nasdaq 5635(c)(4) e sono in linea con i termini del Piano di Incentivazione Azionaria del 2018 dell'azienda.
Replimune Group anunció premios de acciones por inducción para 12 nuevos empleados no ejecutivos. Los premios incluyen opciones sobre acciones no calificadas para comprar 19,390 acciones a $12.02 por acción y unidades de acciones restringidas que representan 38,810 acciones. Las opciones tienen un plazo de 10 años con un 25% que se consolidará después de un año y el resto mensualmente durante tres años. Las unidades de acciones restringidas se consolidan en cuatro pagos anuales a partir del 15 de noviembre de 2025. Estos premios fueron aprobados bajo la Regla de Cotización de Nasdaq 5635(c)(4) y se alinean con los términos del Plan de Incentivo de Acciones de 2018 de la Compañía.
Replimune Group은 12명의 신규 비상무직원을 대상으로 유도 주식 보상을 발표했습니다. 이 보상은 $12.02에 19,390주를 구매할 수 있는 비자격 주식 옵션과 38,810주를 나타내는 제한 주식 단위를 포함합니다. 옵션은 10년의 기간을 가지며 1년 후 25%가 확정되고 나머지는 3년 동안 매달 확정됩니다. 제한 주식 단위는 2025년 11월 15일부터 시작하여 4회의 연간 할부로 확정됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 승인되었으며, 회사의 2018 주식 인센티브 계획의 조건과 일치합니다.
Replimune Group a annoncé des attributions d'actions d'incitation à 12 nouveaux employés non exécutifs. Les attributions comprennent des options d'achat d'actions non qualifiées pour l'achat de 19 390 actions à 12,02 $ par action et des unités d'actions restreintes représentant 38 810 actions. Les options ont une durée de 10 ans avec un vesting de 25% après un an, le reste étant mensualisé sur trois ans. Les unités d'actions restreintes se débloquent en quatre versements annuels à partir du 15 novembre 2025. Ces attributions ont été approuvées conformément à la règle de cotation Nasdaq 5635(c)(4) et sont en accord avec les conditions du Plan d'Incentive en Actions de l'entreprise de 2018.
Die Replimune Group gab Incentive-Aktienvergaben für 12 neu eingestellte Mitarbeiter ohne Exekutivfunktionen bekannt. Die Vergaben umfassen nicht qualifizierte Aktienoptionen zum Kauf von 19.390 Aktien zu je 12,02 $ und eingeschränkte Aktieneinheiten, die 38.810 Aktien repräsentieren. Die Optionen haben eine Laufzeit von 10 Jahren mit 25% Vesting nach einem Jahr und der Rest monatlich über drei Jahre. Die eingeschränkten Aktieneinheiten erlangen in vier jährlichen Raten ab dem 15. November 2025 Vesting. Diese Vergaben wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt und entsprechen den Bedingungen des Aktienoptionsplans des Unternehmens von 2018.
- None.
- None.
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 12 employees as a material inducement to commencing their employment with the Company. The inducement awards consist of non-qualified stock options to purchase an aggregate of 19,390 shares of the Company's common stock and restricted stock units representing an aggregate of 38,810 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of the Company’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under such plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
How many shares were included in Replimune's (REPL) November 2024 inducement grants?
What is the exercise price for Replimune's (REPL) November 2024 stock options grant?
What is the vesting schedule for Replimune's (REPL) November 2024 restricted stock units?
